IMARC Group, a leading global market research and management consulting firm, has published its latest market intelligence report on the Saudi Arabia cell and gene therapy market. The Saudi Arabia cell and gene therapy market size reached USD 234.5 Million in 2025 and is projected to reach USD 1,026.3 Million by 2034, exhibiting a CAGR of 17.82% during 2026-2034, driven by Vision 2030 healthcare transformation, localized therapy manufacturing, and a national focus on affordability and patient access.

Cell and gene therapy benefits from the structural nature of the Kingdom's push for healthcare self-reliance, with every locally manufactured therapy reducing dependence on external suppliers, shortening treatment timelines, and widening access for patients with genetic, oncology, and rare disease needs. The market is forecast to add approximately USD 791.8 Million in incremental value between 2025 and 2034, with three structural forces shaping this trajectory: national localization of advanced therapies, dramatic cost reduction through in-Kingdom manufacturing, and a growing pipeline of international partnerships and investment commitments.

Saudi Arabia Cell and Gene Therapy Market at a Glance:

• Market Size (2025): USD 234.5 Million
• Forecast Market Size (2034): USD 1,026.3 Million
• CAGR (2026-2034): 17.82%
• Historical Period: 2020-2025
• Forecast Period: 2026-2034
• Segmentation Coverage: Therapy Type, Indication, Delivery Mode, End User, and Region

How AI is Reshaping the Future of the Saudi Arabia Cell and Gene Therapy Market

• AI-Enabled Therapy Development: Machine learning tools are helping Saudi research institutions and biotech partners accelerate target identification, optimize vector and cell-line design, and shorten preclinical timelines as the Kingdom builds national research capacity under its biotechnology strategy.
• Smarter Manufacturing and Quality Control: Automation and data-driven process monitoring are supporting the shift to in-country production of CAR-T and other advanced therapies, improving batch consistency, reducing turnaround times, and helping lower per-patient manufacturing costs.
• Data-Driven Patient Matching and Clinical Trials: Advanced analytics are strengthening patient identification, trial recruitment, and outcome tracking across the Kingdom's expanding clinical trial frameworks, supporting faster and more precise delivery of therapies to eligible patients.

Grab a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-cell-gene-therapy-market/requestsample

Saudi Arabia Cell and Gene Therapy Market Trends and Drivers:

A strong national push for therapy localization is the foundational driver behind the market's growth, addressing long-standing reliance on external suppliers, reducing logistical bottlenecks, and improving the availability of life-saving treatments for genetic and rare diseases. In July 2024, Boston Oncology and King Fahd Medical City (KFMC) signed a Letter of Intent to collaborate on localizing cell and gene therapy within the Kingdom, emphasizing national research capacity, expanded clinical trial frameworks, and in-country delivery of advanced medical technologies, in close alignment with Vision 2030's healthcare transformation agenda.

Affordability and scale are compounding this localization momentum with the most tangible commercial impact in the market. In October 2024, King Faisal Specialist Hospital & Research Centre (KFSHRC) began local manufacturing of CAR-T cells, achieving an 80% reduction in therapy costs from SAR 1.3 Million per patient, with plans to scale up to 100 gene therapies annually. The move aligns with Saudi Arabia's National Biotechnology Strategy and Vision 2030, and enhances quality control, accelerates turnaround times, and minimizes treatment delays for patients across the Kingdom.

International partnerships and investment commitments are reshaping the ecosystem on top of these demand drivers. In December 2024, Vertex Pharmaceuticals signed an MoU with Saudi Arabia's ministries on a USD 266 Million initiative to boost local gene therapy manufacturing, supporting R&D, production, and workforce training, while in January 2025, Charles River partnered with Lafana Holding to launch the Saudi Cell and Gene Therapy Accelerator Program, offering CDMO services, investment aid, and advisory support to the biotech ecosystem.

Government Schemes and Vision 2030 Initiatives Driving Demand:

• Vision 2030 Healthcare Transformation: A core pillar of the Kingdom's national agenda, focused on self-reliance, affordability, and innovation to improve patient access and build a strong regional position in advanced therapeutics.
• National Biotechnology Strategy: Aims to create a diversified, innovation-led economy by building domestic biotechnology capability, with in-Kingdom cell and gene therapy manufacturing, such as KFSHRC's local CAR-T production, serving as a flagship application.
• Therapy Localization Partnerships: Collaborations such as the July 2024 Letter of Intent between Boston Oncology and King Fahd Medical City are building national research capacity, expanding clinical trial frameworks, and facilitating in-country delivery of advanced therapies.
• Ministerial Manufacturing Localization Agreement: The December 2024 MoU between Vertex Pharmaceuticals and Saudi Arabia's ministries commits USD 266 Million to local gene therapy R&D, production, and workforce training, advancing access to therapies such as Casgevy.
• Saudi Cell and Gene Therapy Accelerator Program: Launched in January 2025 by Charles River and Lafana Holding, the program supports biotech ecosystem growth through CDMO services, investment aid, and advisory support.

Saudi Arabia Cell and Gene Therapy Industry Segmentation:

The report has segmented the market into the following categories:

Breakup By Therapy Type:

• Cell Therapy
• Stem Cell (Pluripotent Stem Cell, Cancer Stem Cell, Adult Stem Cell)
• Non-Stem Cell (T Cells, Natural Killer, Others)
• Gene Therapy

Cell therapy spans stem cell and non-stem cell approaches, with T cell-based therapies such as locally manufactured CAR-T gaining visibility through domestic production milestones, while gene therapy is being advanced through national manufacturing partnerships and the Kingdom's growing focus on genetic and rare disease treatment.

Breakup By Indication:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

Breakup By Delivery Mode:

• In-Vivo
• Ex-Vivo

Breakup By End User:

• Hospitals
• Cancer Care Centers
• Pharmaceutical & Biotechnology Companies
• Others

Breakup By Region:

• Northern and Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The Saudi Arabia cell and gene therapy market is shaped by leading hospitals and research centers, international biopharmaceutical and CDMO players, and local biotech partners working together to build in-Kingdom capability. The report provides a comprehensive competitive analysis, including detailed profiles of all major companies, covering:

• Market structure
• Key player positioning
• Top winning strategies
• Competitive dashboard
• Company evaluation quadrant

Institutions and companies such as King Faisal Specialist Hospital & Research Centre, King Fahd Medical City, Boston Oncology, Vertex Pharmaceuticals, and Charles River are among those driving localization, manufacturing, and partnership activity across the Kingdom.

What Does The Full Report Cover?

If you are tracking the Saudi Arabia cell and gene therapy market for investment decisions, market entry planning, competitive benchmarking, or strategic advisory, IMARC Group's report gives you everything in one place:

• Complete market sizing in value terms (Million USD) with historical analysis for 2020-2025 and forecasts covering the full 2026-2034 projection period
• Segment-wise historical and future market assessment across therapy type, indication, delivery mode, end user, and region
• Analysis of key market drivers, challenges, and opportunities, including industry catalysts shaping the Kingdom's advanced therapeutics landscape
• Porter's five forces analysis assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution
• Competitive landscape coverage including market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant
• Value chain analysis and latest trends covering therapy localization, cost-reduction strategies, and infrastructure expansion across the Kingdom

Recent News and Developments in Saudi Arabia Cell and Gene Therapy Market

• January 2025: Charles River partnered with Lafana Holding to launch the Saudi Cell and Gene Therapy Accelerator Program, supporting biotech ecosystem growth by offering CDMO services, investment aid, and advisory support while advancing the Kingdom's capabilities and access in the gene therapy sector.
• December 2024: Vertex Pharmaceuticals signed an MoU with Saudi Arabia's ministries to boost local gene therapy manufacturing, with the USD 266 Million initiative supporting R&D, production, and workforce training, advancing access to therapies like Casgevy.
• October 2024: King Faisal Specialist Hospital & Research Centre (KFSHRC) began local manufacturing of CAR-T cells, achieving an 80% reduction in therapy costs from SAR 1.3 Million per patient, with plans to scale up to 100 gene therapies annually.
• July 2024: Boston Oncology and King Fahd Medical City (KFMC) signed a Letter of Intent to collaborate on localizing cell and gene therapy within Saudi Arabia, focusing on national research capacity, clinical trial frameworks, and in-country delivery of advanced medical technologies.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

Key Questions This Report Answers

• How has the Saudi Arabia cell and gene therapy market performed so far and how will it perform in the coming years?
• What is the breakup of the Saudi Arabia cell and gene therapy market by therapy type, indication, delivery mode, end user, and region?
• What are the key drivers and challenges in the Saudi Arabia cell and gene therapy market?
• How are therapy localization, cost reduction, and Vision 2030 reshaping the Saudi Arabia cell and gene therapy industry?
• What are the various stages in the value chain of the Saudi Arabia cell and gene therapy market?
• Who are the key players in the Saudi Arabia cell and gene therapy market and what is the degree of competition?
• What are the investment and market entry opportunities across local manufacturing, clinical infrastructure, and strategic partnerships in Saudi Arabia?

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Media and Sales Contact

IMARC Group

Email: sales@imarcgroup.com

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104